151 related articles for article (PubMed ID: 37395644)
1. Determination of MIC Quality Control Ranges for Ceftibuten-Avibactam (Fixed 4 μg/mL), a Novel β-Lactam/β-Lactamase Inhibitor Combination.
Huband MD; Fedler KA; Sader HS; Stone GG; Castanheira M
J Clin Microbiol; 2023 Jul; 61(7):e0165722. PubMed ID: 37395644
[TBL] [Abstract][Full Text] [Related]
2. Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam.
Belley A; Huband MD; Fedler KA; Watters AA; Flamm RK; Shapiro S; Knechtle P
J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167844
[TBL] [Abstract][Full Text] [Related]
3. Selection of the appropriate avibactam concentration for use with ceftibuten in broth microdilution susceptibility testing.
Sader HS; Lindley J; Deshpande LM; Doyle T; Castanheira M
Diagn Microbiol Infect Dis; 2022 Jun; 103(2):115673. PubMed ID: 35390644
[TBL] [Abstract][Full Text] [Related]
4.
Karlowsky JA; Hackel MA; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2023 Jan; 67(1):e0134622. PubMed ID: 36602322
[TBL] [Abstract][Full Text] [Related]
5. Development of EUCAST zone diameter breakpoints and quality control criteria for ceftazidime-avibactam 10-4 μg.
Koeth LM; Matuschek E; Kahlmeter G; Stone G
Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1047-1053. PubMed ID: 29603034
[TBL] [Abstract][Full Text] [Related]
6.
Karlowsky JA; Hackel MA; Sahm DF
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0130421. PubMed ID: 34662183
[TBL] [Abstract][Full Text] [Related]
7. In vivo pharmacokinetics and pharmacodynamics of ceftibuten/ledaborbactam, a novel oral β-lactam/β-lactamase inhibitor combination.
Fratoni AJ; Avery LM; Nicolau DP; Asempa TE
J Antimicrob Chemother; 2022 Dec; 78(1):93-100. PubMed ID: 36272135
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
9. Determination of MIC Quality Control Ranges for the Novel Gyrase Inhibitor Zoliflodacin.
Miller AA; Traczewski MM; Huband MD; Bradford PA; Mueller JP
J Clin Microbiol; 2019 Sep; 57(9):. PubMed ID: 31315953
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021).
Sader HS; Carvalhaes CG; Huband MD; Mendes RE; Castanheira M
Eur J Clin Microbiol Infect Dis; 2023 Apr; 42(4):453-459. PubMed ID: 36810724
[TBL] [Abstract][Full Text] [Related]
11. Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of
Karlowsky JA; Wise MG; Hackel MA; Pevear DC; Moeck G; Sahm DF
Antimicrob Agents Chemother; 2022 Nov; 66(11):e0093422. PubMed ID: 36286518
[TBL] [Abstract][Full Text] [Related]
12. Sulbactam-durlobactam susceptibility test method development and quality control ranges for MIC and disk diffusion tests.
McLeod SM; Carter NM; Huband MD; Traczewski MM; Bradford PA; Miller AA
J Clin Microbiol; 2024 Jan; 62(1):e0122823. PubMed ID: 38095417
[TBL] [Abstract][Full Text] [Related]
13. Microbiological Characterization of VNRX-5236, a Broad-Spectrum β-Lactamase Inhibitor for Rescue of the Orally Bioavailable Cephalosporin Ceftibuten as a Carbapenem-Sparing Agent against Strains of
Chatwin CL; Hamrick JC; Trout REL; Myers CL; Cusick SM; Weiss WJ; Pulse ME; Xerri L; Burns CJ; Moeck G; Daigle DM; John K; Uehara T; Pevear DC
Antimicrob Agents Chemother; 2021 Jul; 65(8):e0055221. PubMed ID: 34001510
[TBL] [Abstract][Full Text] [Related]
14. Determination of MIC and disk diffusion quality control guidelines for meropenem-vaborbactam, a novel carbapenem/boronic acid β-lactamase inhibitor combination.
Munson E; Huband MD; Castanheira M; Fedler KA; Flamm RK
Diagn Microbiol Infect Dis; 2018 Apr; 90(4):324-328. PubMed ID: 29276104
[TBL] [Abstract][Full Text] [Related]
15. Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in
Le Terrier C; Nordmann P; Bouvier M; Poirel L
Antimicrob Agents Chemother; 2023 Oct; 67(10):e0054723. PubMed ID: 37668385
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a Ceftazidime-Avibactam combination in a murine model of Septicemia caused by Enterobacteriaceae species producing ampc or extended-spectrum β-lactamases.
Levasseur P; Girard AM; Lavallade L; Miossec C; Pace J; Coleman K
Antimicrob Agents Chemother; 2014 Nov; 58(11):6490-5. PubMed ID: 25136016
[TBL] [Abstract][Full Text] [Related]
17. Ceftibuten (7432-S, SCH 39720): comparative antimicrobial activity against 4735 clinical isolates, beta-lactamase stability and broth microdilution quality control guidelines.
Jones RN; Barry AL
Eur J Clin Microbiol Infect Dis; 1988 Dec; 7(6):802-7. PubMed ID: 3145869
[TBL] [Abstract][Full Text] [Related]
18.
Gupta A; Malik S; Kaminski M; Landman D; Quale JM
Microb Drug Resist; 2022 Apr; 28(4):419-424. PubMed ID: 35451880
[TBL] [Abstract][Full Text] [Related]
19. Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity.
Traczewski MM; Ambler JE; Schuch R
J Clin Microbiol; 2021 Jun; 59(7):e0311720. PubMed ID: 33910968
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of novel ciprofloxacin-avibactam conjugates for the development of second-generation non-β-lactam-β-lactamase inhibitors.
Kumar R; Pathania V; Kumar S; Kumar M; Nandanwar H; Maurya SK
Bioorg Med Chem Lett; 2023 May; 88():129308. PubMed ID: 37127102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
